Thinking and memory in people with DLBCL
Part of Blood & lymphatic, Cancer, Immune system & allergy, Mental health clinical trials.
This study looks at how thinking and memory may be affected in people newly diagnosed with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) who are about to start a common chemotherapy regimen known as R-CHOP. It also includes a comparison group of healthy relatives. The goal is to understand how treatment may affect cognitive function over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old
- You have been newly diagnosed with diffuse large B-cell lymphoma (DLBCL)
- Your doctor plans to treat you with R-CHOP chemotherapy (with or without extra chemotherapy into the spinal fluid)
- You are able to understand the study and give your permission (informed consent)
- You do not have a severe memory or thinking problem that would make testing impossible
- You do not have a serious mental health or brain condition that could affect the test results
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
This study looks for biomarkers (biological signs) in blood or tissue samples from people with diffuse large B-cell lymphoma (DLBCL) to help predict how the disease behaves and how well treatment might work. Participation involves giving extra biopsy or blood samples during routine care.
This trial tests if a new drug combination (R-CMOP) works as well as or better than the usual combination (R-CHOP) for people with a type of lymphoma called DLBCL who haven't had treatment yet.
This trial uses a blood test (ctDNA) and PET scans to predict how well standard first-line treatment works for diffuse large B-cell lymphoma (DLBCL). It aims to find out if these tests can guide better care.
This study looks at how lymphoma treatment may affect thinking and memory years after therapy. It aims to understand and support long-term survivors.
This study looks at the biology of certain lymphomas to better understand why some people respond well to treatment and others don't. It involves giving a small additional blood or tissue sample to help researchers find genetic clues that could improve future care.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.